**Supplemental Material:**

**Supplementary Figures**

Fig. S1A: Individual HPV16 kinetics among the 1 dose group:



HPV16

Fig. S1B: Individual HPV18 kinetics among the 1 dose group:



HPV18

Fig. S1C: Individual HPV16 kinetics among the 2-dose(0/1) group:



HPV16

Fig. S1D: Individual HPV18 kinetics among the 2-dose(0/1) group:



HPV18

Fig. S1E: Individual HPV16 kinetics among the 2-dose(0/6) group:



HPV16

Fig. S1F: Individual HPV18 kinetics among the 2-dose(0/6) group:



HPV18

Fig. S1G: Individual kinetics HPV16 among the 3-dose group:



HPV16

Fig. S1H: Individual kinetics HPV18 among the 3-dose group:



HPV18

Fig. S2A: Relation of HPV16 antibody levels at 12 months and 48 months among women who received one vaccine dose.

The red dots represent women whose antibody levels fell below the range of levels at V48 observed among women who received all three doses.

Fig. S2B: Relation of HPV18 antibody levels at 12 months and 48 months among women who received one vaccine dose.

The red dots represent women whose antibody levels fell below the range of levels at V48 observed among women who received all three doses.

**Supplementary Table**

**Table S1: Comparison of selected enrollment characteristics by vaccine dose group**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **1 dose****N=78** | **2 doses****N=192**  | **3 doses****N=120** | **X2 *P*** |
| **Age** | **n(%)** | **n(%)** | **n(%)** |   |
| 18-20 | 38 (48·72) | 93 (48·19) | 56 (46·67) |   |
| 21-25 | 40 (51·28) | 100 (51·81) | 64 (53·33) | 0·95 |
|  |  |  |  |  |
| **Virgin at enrollment** |  |  |  |  |
| No | 56 (71·79) | 163 (84·46) | 88 (73·33) |  |
| Yes | 22 (28·21) | 30 (15·54) | 32 (26·67) | 0·02 |
|  |   |   |   |   |
| **Lifetime partners** |   |   |   |   |
| 0/1 | 52 (66·67) | 96 (49·74) | 78 (65·00) |   |
| 2 | 13 (16·67) | 42 (21·76) | 20 (16·67) |   |
| 3+ | 13 (16·67) | 55 (28·50) | 22 (18·33) | 0·03 |
| **Enrolment HPV infection** |   |   |   |   |
| Negative | 43 (60·56) | 106 (57·30) | 70 (64·22) |   |
| 16 or 18 positive | 3 (4·23) | 14 (7·57) | 3 (2·75) |   |
| Other Carcinogenic | 16 (22·54) | 35 (18·92) | 21 (19·27) |   |
| Non-carcinogenic  | 9 (12·68) | 30 (16·22) | 15 (13·76) | 0·6 |
|  |  |  |  |  |
| **HPV infection over 4 years** |   |   |   |   |
| Negative | 22 (31·88) | 53 (29·28) | 31 (29·25) |   |
| 16 or 18 positive | 3 (4·35) | 12 (6·63) | 5 (4·72) |   |
| Other Carcinogenic | 30 (43·48) | 80 (44·20) | 48 (45·28) |   |
| Non-carcinogenic  | 14 (20·29) | 36 (19·89) | 22 (20·75) | 0·99 |
|  |  |  |  |  |
| **Enrolment smoking status** |  |  |  |  |
| Non-smoker | 74 (94·87) | 160 (82·90) | 103 (85·83) |  |
| Former | 1 (1·28) | 13 (6·74) | 7 (5·83) |  |
| Current | 3 (3·85) | 20 (10·36) | 10 (8·33) | 0·14 |
| **Enrolment hormonal contraceptive** |  |  |  |  |
| No | 29 (37·18) | 57 (29·53) | 43 (35·83) |  |
| Yes | 49 (62·82) | 136 (70·47) | 77 (63·17) | 0·35 |
| **Number of pregnancies** **before enrollment** |  |  |  |  |
| None | 45 (67·16) | 94 (55·29) | 65 (61·90) |  |
| 1 | 16 (23·88) | 53 (31·18) | 36 (34·29) |  |
| 2+ | 6 (8·96) | 23 (13·53) | 4 (3·81) | 0·06 |
| **Enrollment 16 serostatus** |  |  |  |  |
| Negative | 72 (92·31) | 158 (81·87) | 102 (85·00) |  |
| Positive | 6 (7·69) | 35 (18·13) | 18 (15·00) | 0·09 |
| **HPV16 Antibody titers at one month** **past 1st dose (GMT, 95%CI)** |  |  |  |  |
|  | 363·78 (211·98-624·29) | 567·42 (421·76-763·38) \* | 484·59 (368·62-637·04) | 0·81 |
| **HPV18 Antibody titers at one month** **past 1st dose (GMT, 95%CI)** |  |  |  |  |
|  | 207 (114·94-372·81) | 244·06 (184·16-323·4)\* | 207·85 (163·33-264·51) | 0·69 |

\*The GMT and 95% CI presented is for the 2 dose (0/1 month) group. The 2 dose 0/6 group did not have a 1 month visit. CI=confidence interval